2019
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis
Antonia SJ, Borghaei H, Ramalingam SS, Horn L, De Castro Carpeño J, Pluzanski A, Burgio MA, Garassino M, Chow LQM, Gettinger S, Crinò L, Planchard D, Butts C, Drilon A, Wojcik-Tomaszewska J, Otterson GA, Agrawal S, Li A, Penrod JR, Brahmer J. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. The Lancet Oncology 2019, 20: 1395-1408. PMID: 31422028, PMCID: PMC7193685, DOI: 10.1016/s1470-2045(19)30407-3.Peer-Reviewed Original ResearchConceptsPD-L1 expressionCell lung cancerOverall survivalCheckMate 017Progressive diseaseHazard ratioSurvival outcomesLung cancerLong-term survival advantageDose of nivolumabTrials of nivolumabNew safety signalsFour-year survivalLonger overall survivalLonger response durationBristol-Myers SquibbStable diseaseAdvanced NSCLCObjective responsePooled analysisLong-term benefitsNivolumabSafety signalsClinical dataClinical studies
2011
Lung Cancer in Older Patients
Gettinger S, Tanoue L. Lung Cancer in Older Patients. Respiratory Medicine 2011, 89-109. DOI: 10.1007/978-1-60761-727-3_5.Peer-Reviewed Original ResearchYears of ageLung cancerOlder patientsBest supportive careMajority of patientsCancer-related mortalityStandard of careNovel therapeutic approachesLung cancer diagnosisAdvanced diseaseElderly patientsSupportive careMedian ageClinical trialsClinical studiesAggressive approachTherapeutic approachesPatientsCancerOlder populationYounger counterpartsCancer diagnosisAgeMortalityDisease